Presently only the R848 and CpG adjuvanted Hepatitis B vaccines were evaluated in phase III clinical trials against viral infection (NCT00175435, NCT02117934), while a STING agonist is being tested as an adjuvant in cancer immunotherapy but not against viral infections (NCT03172936). The gene discussed is STING1; the disease is cancer.